Impact of renin–angiotensin–aldosterone-system inhibitor drugs on mortality in patients with atrial fibrillation and hypertension

Table 2 Association between ACEI/ARB therapy and one-year outcomes in AF patients with hypertension

Outcomes	Total	ACEI/ARB	no ACEI/ARB	P value	Univariable analysis		Multivariable analysis*
Outcomes	(n = 1110)	(n = 574)	(n = 536)	P value	HR (95%CI)	P value	HR (95% CI)	P value
All-cause death	169 [15.2%]	72 [12.5%]	97 [18.1%]	0.010	0.658 (0.485–0.893)	0.007	0.605 (0.431–0.849)	0.004
Cardiovascular death	100 [9.0%]	48 [8.4%]	52 [9.7%]	0.436	0.778 (0.521–1.162)	0.220	0.585 (0.372–0.921)	0.020
Stroke	98 [8.8%]	46 [8.0%]	52 [9.7%]	0.322	3.391 (0.353–32.602)	0.290	0.721 (0.468–1.111)	0.138
MAEs	255 [23.0%]	112 [19.5%]	143 [24.8%]	0.005	0.692 (0.540–0.886)	0.004	0.651 (0.496–0.855)	0.002

^*Adjusted for age, body mass index, heart rate, heart failure, significant valvular disease, rheumatic heart disease, prior stroke/transient ischemic attack, dementia, chronic obstructive pulmonary disease, diuretic, warfarin, CHADS₂ score ≥ 2, statins, beta-blockers, aspirin, digoxin, and amiodarone

ISSN: 1471-2261